Complement Inhibitors for Macular Degeneration

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$212,118.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43EY019191-01A1
Award Id:
93767
Agency Tracking Number:
EY019191
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NOVELMED THERAPEUTICS, INC., 2265 ENTERPRISE PKWY, TWINSBURG, OH, 44087
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
190155171
Principal Investigator:
REKHA BANSAL
(440) 477-9874
REKHA@NOVELMED.COM
Business Contact:
REKHA BANSAL
() -
rekha@novelmed.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) affects nearly 10 million people in the U.S (Research to Prevent Blindness Foundation). Recently approved anti-VEGF therapy is the only cure for wet AMD as of today. Recent studies have demonstrated the role of the alternative pathway (AP) in AMD. Gradual loss of vision eventually resulting in blindness is the key symptom of AMD in the adult population. Using the mouse AMD model, Bora et al demonstrated that complement factor B of t he alternative pathway plays an important role in the disease. With the use of siRNA techniques, Dr. Bora demonstrated that silencing of the factor B gene prevents the induction and persistence of AMD. Encouraged by these results, we decided to evaluate th e effect of our blocking anti-factor B monoclonal antibody (Bikaciomab) in inhibiting the development and progression of AMD. Bikaciomab binds factor B protein in human blood and blocks its function in AP mediated complement activation. Bikaciomab prevents alternative pathway mediated formation of C3a, C5a, and C5b-9, the key anaphylatoxins responsible for the inflammatory responses. We will test the effect of this blocking anti-factor B antibody in prophylaxis and established models of the disease to provi de direct clinical relevance of the drug under testing. PUBLIC HEALTH RELEVANCE: Age-related macular degeneration (AMD) affects nearly 10 million people in the U.S (Research to Prevent Blindness Foundation). Recently approved anti-VEGF therapy is the only cure for wet AMD as of today. There is an unmet medical need in the area of macular degeneration. NovelMed's current approach focuses on neutralizing factor B function and providing disease benefit. Using the previously developed animal models of AMD, Nove lMed intends to test its lead complement inhibitor for the treatment of AMD. Potent activity of Bikaciomab in vitro, ex vivo and in vivo makes the drug as a potential therapeutic for not only AMD but also for several diseases where alternative pathway play s an important role in disease pathology.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government